ArticleCancer cell international2019
PAX8 expression in high-grade serous ovarian cancer positively regulates attachment to ECM via Integrin β3.
Article in Cancer cell international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Breast and Contralateral Axillary Lymph Node Metastases After Ovarian Cancer Surgery: A Case Report.Clinical case reports · 2026Article
- Automated in situ microfluidic Random-seq for robust single-nucleus and spatial total RNA profiling of diverse FFPE specimens.Nature communications · 2026Article
- zAvatar-test-A functional precision model to personalize ovarian cancer treatments: Results from a co-clinical study.Cell reports. Medicine · 2026Article
- Genomic Profile of Interleukin-6 Secreting Ovarian Cancer: Validation of Future Biomarkers and Target of Therapy.International journal of women's health · 2026Article
- Integrative multi-omic analysis reveals a PAX8-driven gene network linking tumor stemness to therapy response in ovarian cancer.NAR genomics and bioinformatics · 2025Article
- EHMT1 mediates cellular motility in embryonal rhabdomyosarcoma by activating SOX8 expression.British journal of cancer · 2025Article
- Anoikis resistance in Cancer: Mechanisms, therapeutic strategies, potential targets, and models for enhanced understanding.Cancer letters · 2025Review
- Article
- TMEtyper: A computational method for tumor microenvironment subtyping with applications in immunotherapy.Computational and structural biotechnology journal · 2025Article
- Cellular atlases of ovarian microenvironment alterations by diet and genetically-induced obesity.Science China. Life sciences · 2024Article
- Article
- Article
- "DEPHENCE" system-a novel regimen of therapy that is urgently needed in the high-grade serous ovarian cancer-a focus on anti-cancer stem cell and anti-tumor microenvironment targeted therapies.Frontiers in oncology · 2023Review
- Curcumol Targeting PAX8 Inhibits Ovarian Cancer Cell Migration and Invasion and Increases Chemotherapy Sensitivity of Niraparib.Journal of oncology · 2022Article
- PAX8 as a Potential Target for Ovarian Cancer: What We Know so Far.OncoTargets and therapy · 2022Review
- Assessment of the immune landscapes of advanced ovarian cancer in an optimized in vivo model.Clinical and translational medicine · 2021Article
- JMJD2C triggers the growth of multiple myeloma cells via activation of β‑catenin.Oncology reports · 2021Observational
- Unraveling the Mysteries of PAX8 in Reproductive Tract Cancers.Cancer research · 2021Review
- Ovarian Cancer Risk Variants Are Enriched in Histotype-Specific Enhancers and Disrupt Transcription Factor Binding Sites.American journal of human genetics · 2020Article
- Kelch-like protein 14 promotes proliferation and migration of ovarian cancer cells.International journal of clinical and experimental pathology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian cancer is the third most common cause of death among gynecologic malignancies worldwide. Understanding the biology and molecular pathogenesis of ovarian epithelial tumors is key to developing improved prognostic indicators and effective therapies. We aimed to determine the effects of PAX8 expression on the migrative, adhesive and survival capabilities of high-grade serous carcinoma cells.
methodsPAX8 depleted Fallopian tube secretory cells and ovarian cancer cells were generated using short interfering siRNA.
resultsHere, we report that RNAi silencing of PAX8 sensitizes non-adherent cancer cells to
conclusionsOur results demonstrate that PAX8 modulates the interaction of tumor cells with the extracellular matrix (ECM). Notably, we also highlight a novel pathway downstream this transcription factor. Overall, PAX8 could be a potential therapeutic target for high-grade serous carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.